Peptídeos

A synthetic peptide for use as a blocking control in assays to test for specificity of NRP1 antibody, catalog no. 70R-9671

A synthetic peptide for use as a blocking control in assays to test for specificity of POGZ antibody, catalog no. 20R-1216

A synthetic peptide for use as a blocking control in assays to test for specificity of AIFM3 antibody, catalog no. 70R-2470

A synthetic peptide for use as a blocking control in assays to test for specificity of ALDH3A1 antibody, catalog no. 70R-9874

A synthetic peptide for use as a blocking control in assays to test for specificity of CCBP2 antibody, catalog no. 70R-7846

A synthetic peptide for use as a blocking control in assays to test for specificity of C1orf122 antibody, catalog no. 70R-4043

Custom research peptide; min purity 95%.

A synthetic peptide for use as a blocking control in assays to test for specificity of ZCCHC17 antibody, catalog no. 70R-4635

A synthetic peptide for use as a blocking control in assays to test for specificity of PUS1 antibody, catalog no. 70R-10363

A synthetic peptide for use as a blocking control in assays to test for specificity of EDIL3 antibody, catalog no. 70R-9143

A synthetic peptide for use as a blocking control in assays to test for specificity of ABCD4 antibody, catalog no. 70R-1784

A synthetic peptide for use as a blocking control in assays to test for specificity of DYDC1 antibody, catalog no. 70R-4150

A synthetic peptide for use as a blocking control in assays to test for specificity of ZDHHC21 antibody, catalog no. 70R-4550

A synthetic peptide for use as a blocking control in assays to test for specificity of SPTAN1 antibody, catalog no. 70R-2207

A synthetic peptide for use as a blocking control in assays to test for specificity of FAM120C antibody, catalog no. 70R-10170

A synthetic peptide for use as a blocking control in assays to test for specificity of BCO2 antibody, catalog no. 70R-10117

A synthetic peptide for use as a blocking control in assays to test for specificity of CHCHD3 antibody, catalog no. 70R-4356

A synthetic peptide for use as a blocking control in assays to test for specificity of Zfp275 antibody, catalog no. 70R-8773

A synthetic peptide for use as a blocking control in assays to test for specificity of PQLC1 antibody, catalog no. 70R-7332

1-Deoxyfructosyl-Val-His (1DFVH) is a research tool that belongs to the group of activators. It has been shown to activate receptors and ion channels, as well as inhibit antibody production. 1DFVH also has an effect on cell biology, which may be due to its ability to interact with proteins in a variety of ways. 1DFVH binds to the receptor by competitive inhibition and activates the receptor by mimicking the natural ligand. This compound has been shown to activate ion channels in cells through the opening of potassium channels, leading to depolarization and increased calcium influx into cells.

A synthetic peptide for use as a blocking control in assays to test for specificity of CPEB2 antibody, catalog no. 70R-4851

MOG(35-55) human corresponds to amino acids 35 to 55 of the human myelin oligodendrocyte glycoprotein (MOG). It can be used in multiple sclerosis research to induce experimental autoimmune encephalomyelitis (EAE) in mouse and rat models.

A synthetic peptide for use as a blocking control in assays to test for specificity of KCNJ9 antibody, catalog no. 70R-5156

A synthetic peptide for use as a blocking control in assays to test for specificity of CYP2R1 antibody, catalog no. 70R-8833

A synthetic peptide for use as a blocking control in assays to test for specificity of DUS1L antibody, catalog no. 70R-4013

A synthetic peptide for use as a blocking control in assays to test for specificity of UBE2L3 antibody, catalog no. 70R-3085

A synthetic peptide for use as a blocking control in assays to test for specificity of LANCL2 antibody, catalog no. 70R-2713

Custom research peptide; min purity 95%.

A synthetic peptide for use as a blocking control in assays to test for specificity of SORD antibody, catalog no. 70R-10245

A synthetic peptide for use as a blocking control in assays to test for specificity of RPAIN antibody, catalog no. 70R-8518

A synthetic peptide for use as a blocking control in assays to test for specificity of GJA8 antibody, catalog no. 70R-6106

A synthetic peptide for use as a blocking control in assays to test for specificity of Gcom1 antibody, catalog no. 70R-3275

A synthetic peptide for use as a blocking control in assays to test for specificity of C21orf13 antibody, catalog no. 70R-1973

Custom research peptide; min purity 95%.

AMC is a peptide that acts as an activator of the nicotinic acetylcholine receptor. AMC is a high-purity, ion channel ligand with a CAS No. 26093-31-2. It is used in life science research to study cell biology and pharmacology. AMC has been shown to be an inhibitor of the enzyme acetylcholinesterase (AChE) in rat brain slices and it has been reported that it can inhibit the proliferation of human leukemia cells.END>

Custom research peptide; min purity 95%.

This product has disulfide bonds between Cys1-Cys15 and Cys3-Cys11 and is available as a 0.1mg vial. Big Endothelin-1 (Human, 1-38) is part of the full lengthed 29 amino acid peptide Big Endothlin-1 which is a precursor peptide of the vasoconstrictorEndothelin-1 (ET-1). ET-1 exhibits vasoconstrictive properties and is an activator of endothelin G-protein coupled receptors. Furthermore ET-1 is produced when inflammation, vascular stress or hypoxia occurs. In vivo Big Endothelin-1 has a greater half life compared to ET-1 and therefore makes it useful to study secretory activity in the endothelial system.
Overall Big Endothelin-1 (Human, 1-38) can be used as a research tool for studying protein interactions, receptor activation and function, and ligand binding. This peptide is also used in pharmacology to study the effects of therapeutic agents on receptor activity and expression.

A synthetic peptide for use as a blocking control in assays to test for specificity of Vamp1 antibody, catalog no. 70R-9793

A synthetic peptide for use as a blocking control in assays to test for specificity of DFFA antibody, catalog no. 20R-1064

Cysteine peptide (Ac RFAAKAA COOH) is used in combination with Lysinepeptide (Ac RFAACAA COOH) in the Direct Peptide Reactivity Assay (DPRA) test.
Direct Peptide Reactivity Assay is used in cosmetic applications for the characterization of the skin sensitizing potential of a substance, framed by OECD Guideline no 442.
The molecular initiating event (MIE) in skin sensitization is a binding between epidermal proteins and the sensitizing chemical substance. MIE is part of the adverse outcome pathway (AOP) of skin sensitization.
It is thanks to the properties of Lysine peptide and Cysteine peptide that the chemical binding will be able to take place, so these synthetic heptapeptides will mimic the reaction of a skin exposed to a substance.
Binding between nucleophilic proteins and electrophile substance will be measured by High Performance Liquid Chromatography (HPLC). Therefore, the decrease in Lysine peptide and Cysteine peptide levels will be a sign of sensitizing event. Depending on the rate of depletion, the sensitizing character of a molecule will be determined (see table at the bottom of the page).
In chemico DPRA test also has wider applications such as hazard classification in cosmetics, but also for pharmaceuticals and biocides. It is a good alternative to animal experimentation.

A synthetic peptide for use as a blocking control in assays to test for specificity of PCMT1 antibody, catalog no. 70R-1558

A synthetic peptide for use as a blocking control in assays to test for specificity of FCRL1 antibody, catalog no. 70R-1853

A synthetic peptide for use as a blocking control in assays to test for specificity of ASL antibody, catalog no. 70R-1176

The LRG1 Blocking Peptide is a highly effective monoclonal antibody that acts as a phosphatase inhibitor in Life Sciences research. This neutralizing peptide is widely used in the field of monoclonal antibodies and has been proven to effectively block the activity of LRG1, a glycoprotein involved in various biological processes.

A synthetic peptide for use as a blocking control in assays to test for specificity of Pcyt2 antibody, catalog no. 70R-9234

A synthetic peptide for use as a blocking control in assays to test for specificity of TTC5 antibody, catalog no. 70R-2121

A synthetic peptide for use as a blocking control in assays to test for specificity of HSPE1 antibody, catalog no. 70R-4219

A synthetic peptide for use as a blocking control in assays to test for specificity of ACAT2 antibody, catalog no. 70R-1083

H-His-Arg-OH is a synthetic peptide that has been shown to have cytotoxic effects on mammalian cells. The H-His-Arg-OH peptide can be used for the treatment of heart disease and autoimmune diseases, such as rheumatoid arthritis. This peptide has been found to be resistant to congestive heart failure, which is caused by a number of factors, including hypertension and valvular stenosis. It has also been shown to have an immunoglobulin G1 (IgG1) genotype.

Catalogue peptide; min. 95% purity

Myelin oligodendrocyte glycoprotein (MOG) is a myelin protein found in the central nervous system. MOG is a ligand for CD200, which is an inhibitory receptor expressed by astrocytes. It has been shown that MOG can induce the proliferation and differentiation of primary cultures of rat astrocytes in vitro. MOG induces the production of reactive oxygen species in mitochondria and increases the expression of acid-binding protein, which are both important factors in the demyelination process. MOG has also been implicated as a potential factor in the development of multiple sclerosis. Further research into this protein may lead to new treatments or cures for disorders such as encephalomyelitis, nervous system diseases, or even cancer.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

CJC-1295 is a synthetic peptide, which is an analogue of growth hormone-releasing hormone (GHRH). It is synthesized through recombinant DNA technology, which allows for precise control over its sequence and length. This particular peptide is designed to bind to GHRH receptors in the pituitary gland. By activating these receptors, CJC-1295 stimulates the release of growth hormone (GH) into the bloodstream.The primary function of CJC-1295 is to influence the endocrine system, particularly enhancing the release of endogenous growth hormone. It achieves this by increasing the amplitude and frequency of GH pulses without affecting the natural negative feedback mechanisms that regulate GH production. This mode of action distinguishes CJC-1295 from other growth hormone therapies, as it promotes a more physiological pattern of hormone secretion.CJC-1295 is used in various scientific contexts, primarily in research focusing on growth hormone deficiencies, muscle wasting conditions, and certain metabolic disorders. Its ability to increase GH release also makes it a subject of interest in studies related to aging, tissue repair, and regeneration. The longer half-life of CJC-1295 compared to natural GHRH peptides further enhances its applications in research, allowing for more sustained and controlled experimentation.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Please enquire for more information about Fluorescein-6-carbonyl-Leu-Glu(OMe)-His-DL-Asp(OMe)-fluoromethylketone including the price, delivery time and more detailed product information at the technical inquiry form on this page

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity